Abstract:Tenascin C (TNC), a glycoprotein that is abundant in the tumor extracellular matrix (ECM), is strongly overexpressed in tumor tissues but virtually undetectable in most normal tissues. Many TNC antibodies, peptides, aptamers, and nanobodies have been investigated as delivery vectors, including 20A1, α-A2, α-A3, α-IIIB, α-D, BC-2, BC-4 BC-8, 81C6, ch81C6, F16, FHK, Ft, Ft-NP, G11, G11-iRGD, GBI-10, 19H12, J1/TN1, J1/TN2, J1/TN3, J1/TN4, J1/TN5, NJT3, NJT4, NJT6, P12, PL1, PL3, R6N, SMART, ST2146, ST2485, TN11, TN12, TNFnA1A2-Fc, TNfnA1D-Fc, TNfnBD-Fc, TNFnCD-Fc, TNfnD6-Fc, TNfn78-Fc, TTA1, TTA1.1, and TTA1.2. In particular, BC-2, BC-4, 81C6, ch81C6, F16, FHK, G11, PL1, PL3, R6N, ST2146, TN11, and TN12 have been tested in human tissues. G11-iRGD and simultaneous multiple aptamers and arginine–glycine–aspartic acid (RGD) targeting (SMART) may be assessed in clinical trials because G11, iRGD and AS1411 (SMART components) are already in clinical trials. Many TNC-conjugate agents, including antibody–drug conjugates (ADCs), antibody fragment–drug conjugates (FDCs), immune-stimulating antibody conjugates (ISACs), and radionuclide–drug conjugates (RDCs), have been investigated in preclinical and clinical trials. RDCs investigated in clinical trials include 111 In-DTPA-BC-2, 131 I-BC-2, 131 I-BC-4, 90 Y-BC4, 131 I81C6, 131 I-ch81C6, 211 At-ch81C6, F16 124 I, 131 I-tenatumomab, ST2146biot, FDC 131 I-F16S1PF(ab')2, and ISAC F16IL2. ADCs (including FHK-SSL-Nav, FHK-NB-DOX, Ft-NP-PTX, and F16*-MMAE) and ISACs (IL12-R6N and 125 I-G11-IL2) may enter clinical trials because they contain components of marketed treatments or agents that were investigated in previous clinical studies. This comprehensive review presents historical perspectives on clinical advances in TNC-conjugate agents to provide timely information to facilitate tumor-targeting drug development using TNC.

Challenges in Antibody Development against Tn and Sialyl-Tn Antigens

Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity

Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2-6 sialic acids

Sialyl-Tn Polysaccharide A1 as an Entirely Carbohydrate Immunogen: Synthesis and Immunological Evaluation

Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model

Sialyl-Tn serves as a potential therapeutic target for ovarian cancer

Targeting cancer-associated glycosylation for adoptive T cell therapy of gastro-intestinal and gynecological cancers

Synthetic and immunological studies of N-acyl modified S-linked STn derivatives as anticancer vaccine candidates

Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy

Antibody-linked cytotoxic agents in the treatment of cancer: current status and future prospects

Sialyl-Tn glycan epitope as a target for pancreatic cancer therapies

Enhancement of the Immunogenicity of Synthetic Carbohydrate Vaccines by Chemical Modifications of STn Antigen.

Progress on Phage Display Technology: Tailoring Antibodies for Cancer Immunotherapy

Advancement of Sialyltransferase Inhibitors: Therapeutic Challenges and Opportunities

Clinical advances in TNC delivery vectors and their conjugate agents

Development of antibody therapeutics for small cell lung cancer.

Synthesis and Immunological Evaluation of N-acyl Modified Tn Analogues As Anticancer Vaccine Candidates.

Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21

Cancer Antibody Engineering: Comparison of Mammalian, Yeast, Bacterial, Plants, Cell-free and Hybridoma Expression Systems

Antibody drug conjugates in recurrent or metastatic cervical cancer: a focus on tisotumab vedotin state of art

Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering